4//SEC Filing
Jewell Christopher M 4
Accession 0001453687-24-000061
CIK 0001453687other
Filed
Apr 9, 8:00 PM ET
Accepted
Apr 10, 9:35 PM ET
Size
11.9 KB
Accession
0001453687-24-000061
Insider Transaction Report
Form 4
Jewell Christopher M
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-04-08−4,276.454→ 0 totalExercise: $107.59Exp: 2033-01-15→ Series A Non-Voting Convertible Preferred Stock (4,276.454 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-04-08+142,547→ 142,547 totalExercise: $3.23Exp: 2033-01-15→ Common Stock (142,547 underlying)
Holdings
- 25,940
Common Stock
- 33,265
Stock Option (Right to Buy)
Exercise: $19.66Exp: 2034-01-01→ Common Stock (33,265 underlying)
Footnotes (6)
- [F1]On April 4, 2024, the issuer effected a 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock ("Common Stock"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.
- [F2]On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved the Reverse Stock Split and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. Prior to the Automatic Conversion, the option was exercisable for 2,984.676 shares of Series A Non-Voting Convertible Preferred Stock of the issuer ("Series A Preferred Stock") and would have become exercisable for an additional 89.093 shares each month until it was fully exercisable on June 16, 2025.
- [F3]On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition.
- [F4]Following the Automatic Conversion, the option is currently exercisable for 99,483 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until is is fully exercisable on June 16, 2025.
- [F5]Following the Automatic Conversion, options previously exercisable for shares of Series A Preferred Stock may be exercised solely for shares of Common Stock.
- [F6]This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.
Documents
Issuer
Cartesian Therapeutics, Inc.
CIK 0001453687
Entity typeother
Related Parties
1- filerCIK 0002000226
Filing Metadata
- Form type
- 4
- Filed
- Apr 9, 8:00 PM ET
- Accepted
- Apr 10, 9:35 PM ET
- Size
- 11.9 KB